Late thrombosis after double versus single drug-eluting stent in the treatment of coronary bifurcations: a meta-analysis of randomized and observational Studies
- PMID: 23769650
- DOI: 10.1016/j.jcin.2013.03.012
Late thrombosis after double versus single drug-eluting stent in the treatment of coronary bifurcations: a meta-analysis of randomized and observational Studies
Abstract
Objectives: This study sought to hypothesize that the higher risk of myocardial infarction (MI) documented after a routine double drug-eluting stent (DES) strategy (DDS) compared with a single DES strategy (SDS) with provisional stenting in percutaneous coronary interventions (PCI) of bifurcation lesions is driven by an increased rate of DES thrombosis.
Background: The results of currently available randomized, controlled trials (RCTs) were inconclusive in the choice between SDS and DDS. Meta-analyses have shown an increased risk of MI in the DDS group, without identifying the underlying mechanism(s).
Methods: We performed a meta-analysis of 12 major (>100 patients) studies of bifurcation DES PCI: 5 RCTs and 7 nonrandomized observational studies, for a total of 6,961 patients. Random-effects models were used to calculate summary risk ratios (RRs). As a primary endpoint, we assessed the RRs and 95% confidence intervals (CIs) of definite DES thrombosis; death, MI, and target vessel revascularization (TVR) were evaluated as secondary endpoints.
Results: Compared with SDS, DDS had an increased risk of DES thrombosis (RR: 2.31; 95% CI: 1.33 to 4.03) and MI (RR: 1.86; 95% CI: 1.34 to 2.60). Mortality (RR: 1.18; 95% CI: 0.85 to 1.65) and TVR (RR: 1.02; 95% CI: 0.80 to 1.30) were similar. The RRs of MI and DES thrombosis were associated (p = 0.040).
Conclusions: In PCI of coronary bifurcations, SDS should be the preferred approach, as DDS is associated with an increased risk of MI, likely driven by DES thrombosis.
Keywords: CI; DDS; DES; MI; PCI; RCT; RR; SDS; TVR; confidence interval; coronary bifurcation; double drug-eluting stent strategy; drug-eluting stent thrombosis; drug-eluting stent(s); myocardial infarction; nROS; nonrandomized, observational study; percutaneous coronary intervention; randomized, controlled trial; relative risk; single drug-eluting stent strategy; target vessel revascularization.
Copyright © 2013. Published by Elsevier Inc.
Comment in
-
The complexity of stenting in bifurcation coronary lesions.JACC Cardiovasc Interv. 2013 Jul;6(7):696-7. doi: 10.1016/j.jcin.2013.04.005. JACC Cardiovasc Interv. 2013. PMID: 23866181 No abstract available.
Similar articles
-
Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.JACC Cardiovasc Interv. 2013 Aug;6(8):777-89. doi: 10.1016/j.jcin.2013.04.011. JACC Cardiovasc Interv. 2013. PMID: 23968698 Clinical Trial.
-
Bare-metal stent versus drug-eluting stent in large coronary arteries: meta-analysis of randomized controlled trials.Catheter Cardiovasc Interv. 2013 Jun 1;81(7):1087-94. doi: 10.1002/ccd.24599. Epub 2013 Feb 26. Catheter Cardiovasc Interv. 2013. PMID: 22899538 Clinical Trial.
-
The Role of Vascular Imaging in Guiding Routine Percutaneous Coronary Interventions: A Meta-Analysis of Bare Metal Stent and Drug-Eluting Stent Trials.Cardiovasc Ther. 2015 Dec;33(6):360-6. doi: 10.1111/1755-5922.12160. Cardiovasc Ther. 2015. PMID: 26363283 Review.
-
5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).JACC Cardiovasc Interv. 2013 Dec;6(12):1263-6. doi: 10.1016/j.jcin.2013.07.009. Epub 2013 Nov 13. JACC Cardiovasc Interv. 2013. PMID: 24239202 Clinical Trial.
-
Meta-analysis of bioabsorbable versus durable polymer drug-eluting stents in 20,005 patients with coronary artery disease: an update.Catheter Cardiovasc Interv. 2014 May 1;83(6):E193-206. doi: 10.1002/ccd.25416. Epub 2014 Feb 10. Catheter Cardiovasc Interv. 2014. PMID: 24478247 Review.
Cited by
-
Comparison of Sequential POT-Side-POT and Kissing Balloon Techniquesin Patientswith Coronary Bifurcation Lesions Treatedwith Single-Stent Strategy; Which One is Simple and Safe? Propensity Score Analysis.Anatol J Cardiol. 2022 Jul;26(7):559-566. doi: 10.5152/AnatolJCardiol.2022.1136. Anatol J Cardiol. 2022. PMID: 35791712 Free PMC article.
-
The Role of Bioresorbable Scaffolds in Meeting the Challenges of Bifurcations.Interv Cardiol. 2013 Aug;8(2):87-89. doi: 10.15420/icr.2013.8.2.87. Interv Cardiol. 2013. PMID: 29588756 Free PMC article.
-
Side branch healing patterns of the Tryton dedicated bifurcation stent: a 1-year optical coherence tomography follow-up study.Int J Cardiovasc Imaging. 2014 Dec;30(8):1445-56. doi: 10.1007/s10554-014-0504-y. Epub 2014 Jul 26. Int J Cardiovasc Imaging. 2014. PMID: 25062748
-
Comparative Computed Flow Dynamic Analysis of Different Optimization Techniques in Left Main Either Provisional or Culotte Stenting.J Transl Int Med. 2017 Dec 29;5(4):205-212. doi: 10.1515/jtim-2017-0035. eCollection 2017 Dec. J Transl Int Med. 2017. PMID: 29340277 Free PMC article.
-
Heparin-Tagged PLA-PEG Copolymer-Encapsulated Biochanin A-Loaded (Mg/Al) LDH Nanoparticles Recommended for Non-Thrombogenic and Anti-Proliferative Stent Coating.Int J Mol Sci. 2021 May 21;22(11):5433. doi: 10.3390/ijms22115433. Int J Mol Sci. 2021. PMID: 34063962 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous